These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16621050)

  • 1. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Konitsiotis S; Tsironis C
    Behav Brain Res; 2006 Jun; 170(2):337-41. PubMed ID: 16621050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
    Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Nepoklonov AV; Kokshenev II; Voronina TA; Val'dman EA
    Eksp Klin Farmakol; 2011; 74(7):9-12. PubMed ID: 21894760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
    Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA
    Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Buck K; Ferger B
    Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Kokshenev II; Nepoklonov AV; Val'dman EA; Voronina TA
    Eksp Klin Farmakol; 2014; 77(5):3-5. PubMed ID: 25033563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
    Larramendy C; Taravini IR; Saborido MD; Ferrario JE; Murer MG; Gershanik OS
    Behav Brain Res; 2008 Dec; 194(1):44-51. PubMed ID: 18638507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
    Marin C; Jiménez A; Bonastre M; Vila M; Agid Y; Hirsch EC; Tolosa E
    Synapse; 2001 Oct; 42(1):40-7. PubMed ID: 11668589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.